299 related articles for article (PubMed ID: 25125553)
1. Relvar Ellipta for asthma.
Drug Ther Bull; 2014 Aug; 52(8):93-6. PubMed ID: 25125553
[TBL] [Abstract][Full Text] [Related]
2. ▼Relvar Ellipta for COPD.
Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
[TBL] [Abstract][Full Text] [Related]
3. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
McKeage K
Drugs; 2014 Sep; 74(13):1509-22. PubMed ID: 25074268
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.
Wolthers OD
Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):144-50. PubMed ID: 26581314
[TBL] [Abstract][Full Text] [Related]
5. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
Matera MG; Capuano A; Cazzola M
Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
[TBL] [Abstract][Full Text] [Related]
6. The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.
Albertson TE; Richards JR; Zeki AA
Ther Adv Respir Dis; 2016 Feb; 10(1):43-56. PubMed ID: 26668137
[TBL] [Abstract][Full Text] [Related]
7. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
[TBL] [Abstract][Full Text] [Related]
8. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy.
Hozawa S; Terada M; Haruta Y; Hozawa M
Pulm Pharmacol Ther; 2016 Apr; 37():15-23. PubMed ID: 26850307
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy.
Albertson TE; Bullick SW; Schivo M; Sutter ME
Drug Des Devel Ther; 2016; 10():4047-4060. PubMed ID: 28008228
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
Oliver A; VanBuren S; Allen A; Hamilton M; Tombs L; Inamdar A; Kempsford R
Clin Ther; 2014 Jun; 36(6):928-939.e1. PubMed ID: 24793536
[TBL] [Abstract][Full Text] [Related]
11. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
[TBL] [Abstract][Full Text] [Related]
13. vilanterol + fluticasone (RELVAR Ellipta). Asthma and COPD: yet another beta-2 agonist and corticosteroid combination.
Prescrire Int; 2016 Apr; 25(170):94. PubMed ID: 27186620
[TBL] [Abstract][Full Text] [Related]
14. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
[TBL] [Abstract][Full Text] [Related]
15. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
[TBL] [Abstract][Full Text] [Related]
16. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
Bollmeier SG; Prosser TR
Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
[TBL] [Abstract][Full Text] [Related]
17. Fluticasone furoate/vilanterol: a review of its use in patients with asthma.
Syed YY
Drugs; 2015 Mar; 75(4):407-18. PubMed ID: 25648266
[TBL] [Abstract][Full Text] [Related]
18. Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD.
Caramori G; Chung KF; Adcock IM
Int J Chron Obstruct Pulmon Dis; 2014; 9():249-56. PubMed ID: 24596460
[TBL] [Abstract][Full Text] [Related]
19. Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
Caramori G; Ruggeri P; Casolari P; Chung KF; Girbino G; Adcock IM
Expert Rev Respir Med; 2017 Dec; 11(12):955-967. PubMed ID: 28956463
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]